About | Free Trial

Last Update


This profile was last updated on // .

Is this you? Claim your profile.

Wrong Thomas Schaible?

Dr. Thomas Schaible F. PhD

Vice President of Medical Affairs

Centocor , Inc.

Direct Phone: (610) ***-****       

Centocor , Inc.

200 Great Valley Pkwy

Malvern, Pennsylvania 19355

United States

Company Description

Centocor, Inc. is a biopharmaceutical company that creates, acquires and markets therapies that yield long-term benefits for patients and the healthcare community. The Company has four therapeutic products approved for sale. ReoPro is approved for the red ... more

Find other employees at this company (878)

Background Information

Employment History

Scientific and Medical Commercial Support
Janssen Biotech , Inc.

Assistant Professor of Medicine and Physiology
Albert Einstein College of Medicine

National - Medical Affairs
Centocor Ortho Biotech , Inc.

Clinical Research Scientist
Berlex , Inc.

Manager, Clinical Development Program



Trinity College

Rutgers University

Web References (92 Total References)

Speakers - Life Sciences Future - It's Here

lifesciencesfuture.com [cached]

Thomas Schaible, Ph.D. Formerly Vice President, Medical Affairs, Janssen Biotech

Bio Thomas F. Schaible, Ph.D. is the Vice President, Medical Affairs, Janssen Biotech, Inc. (JBI), which was formerly Centocor. He leads the scientific and medical commercial support for JBI's marketed products and serves on JBI's Management Board.
Since joining Centocor in 1987 in the Clinical Research group, Dr. Schaible has been an important contributor to Centocor's success. He led the teams that gained the approval for the use of Remicade in treating Crohn's disease in 1998 and rheumatoid arthritis in 1999, for which he received the Johnson Medal, the highest award for research innovation at Johnson and Johnson. He then started the Medical Affairs organization and has responsibility for the post-marketing research and educational initiatives that has supported Remicade's growth since its approval. The JBI Medical Affairs organization now supports a portfolio of immunology products (Remicade, Stelara and Simponi), oncology products (Doxil and Zytiga) and a nephrology product (Procrit). His organization is responsible for all phase IIIb/IV clinical trials, observational registries, as well as investigator-initiated trials. The organization also includes a group based in Leiden, The Netherlands that provides post-marketing support to support our strategic partner, Merck, for sales and marketing of Remicade and Simponi in the European territories.
Prior to joining Centocor, Tom was an Assistant Professor of Medicine and Physiology at the Albert Einstein College of Medicine in New York where he was the recipient of NIH RO1 grants and an NIH Research Career Development Award.
Dr. Schaible holds a Bachelor of Science degree in Biology from Trinity College and a Ph.D. in Physiology from Rutgers University. He did his Postdoctoral Fellowship in Cardiac Physiology and Biochemistry at the Albert Einstein College of Medicine.

"You can make a case that ...

www.knee1.com [cached]

"You can make a case that the incidence of lymphomas is in the range you would expect to see in rheumatoid arthritis," said Tom Schaible of Centocor Inc., Remicade's maker.

Knee1.com - U.S. Debates Risks of 4 Arthritis Drugs

www.knee1.com [cached]

"You can make a case that the incidence of lymphomas is in the range you would expect to see in rheumatoid arthritis," said Tom Schaible of Centocor Inc., Remicade's maker.

Likewise, the trial testimony of ...

www.ccalp.com [cached]

Likewise, the trial testimony of Dr. Thomas Schaible, Centocor's Vice President of Medical Affairs, confirmed that Centocor had knowledge of Remicade's hepatotoxicity and the association of Remicade treatment with liver failure.

The Hamiltons called Thomas ...

www.morelaw.com [cached]

The Hamiltons called Thomas Schiable, the vice president of medical affairs for Centocor, who testified about a scientific study scheduled to be published in the New England Journal of Medicine on February 13, 2003, demonstrating that problems with Remicade had been understated.

Patricia and Thomas, however, denied that Dr. Hauptman ever discussed the risk of lupus-like syndrome.
Thomas testified that Patricia was in so much pain that she could not dress herself or perform her normal functions.
The jury also awarded Thomas $50,000.00 for loss of consortium and household services.
The jury found that the fraud was established by clear and convincing evidence, and it awarded Patricia $15 million and Thomas $1 million in exemplary damages for Centocor's fraudulent conduct.
Before entry of judgment, Drs. Hauptman and Pop-Moody settled with the Hamiltons, and the Hamiltons non-suited those defendants. (14) The trial court applied settlement credits and apportioned responsibility, entered judgment against Centocor based on the fraud claim, and awarded actual and punitive damages and interest, for a total award of $4,687,461.70 to Patricia and $120,833.71 to Thomas against Centocor.
Patricia's husband, Thomas, testified that she could no longer perform her daily functions, including caring for her colostomy. This pain, while temporarily relieved by the Remicade infusions, persisted from March of 2001 until October of 2003, when she was weaned off Remicade.
By its eleventh issue, Centocor argues that because Thomas's claims are derivative of Patricia's claims and Patricia cannot recover, we must reverse the award of loss of consortium and household services to Thomas.
The jury awarded Thomas $50,000.00 for loss of consortium and household services.

Similar Profiles

Other People with this Name

Other people with the name Schaible

Kerry Schaible
Northwestern Mutual Wealth Management Company

Michael Schaible

T. Schaible
Kistler Tiffany Benefits

Shaila Schaible
Higgs Fletcher & Mack LLP

Evan Schaible

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory